CohBar Completes IPO To Develop Mitochondrial-Derived Therapeutics
Monday, January 26, 2015 - 05:50
in Mathematics & Economics
CohBar, Inc., a biotechnology company focused on discovering mitochondrial-derived peptides and developing them into therapeutics, completed an Initial Public Offering (IPO) of 11,250,000 units at a price of $1.00 each. All units consist of one share of CohBar's common stock and one-half of one common stock purchase warrant. read more